Introduction
FLUCOSTAT I.V. Infusion X100ML is an antifungal medication widely used in hospitals and healthcare settings for the treatment of severe fungal infections. It is administered through intravenous infusion, making it especially useful for patients who cannot take oral medication or require rapid, effective treatment.
With its active ingredient, fluconazole, FLUCOSTAT I.V. Infusion helps manage life-threatening infections by stopping the growth of fungi inside the body.
Uses of FLUCOSTAT I.V. Infusion X100ML
This antifungal infusion is prescribed for a wide range of fungal infections, particularly in patients with weakened immune systems. Common uses include:
- Systemic fungal infections such as candidiasis and cryptococcosis
- Meningitis caused by Cryptococcus (fungal infection affecting the brain and spinal cord)
- Candidemia (fungal infection in the bloodstream)
- Prevention of fungal infections in patients undergoing chemotherapy, organ transplantation, or other treatments that suppress immunity
- Severe cases of oral, vaginal, and esophageal candidiasis where oral therapy is not possible
Ingredients of FLUCOSTAT I.V. Infusion X100ML
The main active ingredient is:
Fluconazole – an antifungal agent belonging to the triazole group.
The infusion also contains sterile water and stabilising agents that ensure safe and effective intravenous delivery.
How FLUCOSTAT I.V. Infusion Works
FLUCOSTAT I.V. Infusion works by inhibiting the synthesis of ergosterol, an essential component of the fungal cell membrane. Without ergosterol, the fungal cell walls become weak, leading to leakage and cell death.
By disrupting fungal growth and replication, FLUCOSTAT helps eliminate infections from the bloodstream and tissues, providing relief and preventing complications.
Dosage of FLUCOSTAT I.V. Infusion X100ML
The dosage of FLUCOSTAT I.V. Infusion depends on the type and severity of infection, as well as the patient’s age, weight, and medical condition.
- For systemic candidiasis or candidemia: 400 mg on the first day, followed by 200–400 mg daily.
- For cryptococcal meningitis: 400 mg on the first day, then 200–400 mg daily for several weeks.
- For prophylaxis in immunocompromised patients: 200–400 mg daily.
- The infusion is administered slowly through an intravenous line under medical supervision. The duration of treatment can range from a few days to several weeks, depending on the infection.
Important: Dosage must be prescribed by a healthcare professional. Do not self-administer.
Side Effects of FLUCOSTAT I.V. Infusion
While FLUCOSTAT is generally well-tolerated, some patients may experience side effects.
- Headache
- Nausea and vomiting
- Abdominal pain
- Rash or mild skin reactions
- Diarrhoea
- Liver damage (yellowing of skin or eyes, dark urine)
- Severe allergic reactions (swelling, breathing difficulty, hives)
- Irregular heartbeat or chest pain
- Seizures in extremely rare cases
If severe reactions occur, medical attention must be sought immediately.
Frequently Asked Questions (FAQs)
1. What is FLUCOSTAT I.V. Infusion X100ML used for?
It is used for treating severe systemic fungal infections and preventing fungal infections in immunocompromised patients.
2. How is FLUCOSTAT I.V. administered?
It is given as a slow intravenous infusion by a healthcare professional.
3. Can pregnant women use FLUCOSTAT I.V. Infusion?
It should only be used if absolutely necessary and prescribed by a doctor, as high doses may pose risks during pregnancy.
4. How long does the treatment last?
Treatment duration varies from a few days to several weeks, depending on the infection type and severity.
5. Can FLUCOSTAT I.V. Infusion be used in children?
Yes, but the dosage is carefully adjusted based on body weight and medical condition.
Conclusion
FLUCOSTAT I.V. Infusion X100ML is a powerful antifungal treatment designed for severe and systemic fungal infections. With fluconazole as its active ingredient, it effectively stops fungal growth and provides relief in conditions such as candidemia, cryptococcal meningitis, and fungal infections in immunocompromised patients.
